CN117677395A - 长效glp1/胰高血糖素受体激动剂的剂量方案 - Google Patents

长效glp1/胰高血糖素受体激动剂的剂量方案 Download PDF

Info

Publication number
CN117677395A
CN117677395A CN202280051207.4A CN202280051207A CN117677395A CN 117677395 A CN117677395 A CN 117677395A CN 202280051207 A CN202280051207 A CN 202280051207A CN 117677395 A CN117677395 A CN 117677395A
Authority
CN
China
Prior art keywords
agonist
compound
patients
dose
interval
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280051207.4A
Other languages
English (en)
Chinese (zh)
Inventor
M·代施
A·M·亨尼格
C·I·肖尔奇
C·塔默
J·P·M·伯格斯特兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN117677395A publication Critical patent/CN117677395A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202280051207.4A 2021-07-30 2022-07-28 长效glp1/胰高血糖素受体激动剂的剂量方案 Pending CN117677395A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21188741.9 2021-07-30
EP21188741 2021-07-30
PCT/EP2022/071281 WO2023006923A1 (en) 2021-07-30 2022-07-28 Dose regimen for long-acting glp1/glucagon receptor agonists

Publications (1)

Publication Number Publication Date
CN117677395A true CN117677395A (zh) 2024-03-08

Family

ID=77155646

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280051207.4A Pending CN117677395A (zh) 2021-07-30 2022-07-28 长效glp1/胰高血糖素受体激动剂的剂量方案

Country Status (10)

Country Link
US (1) US20250262279A1 (https=)
EP (1) EP4376871A1 (https=)
JP (1) JP2024529452A (https=)
KR (1) KR20240043778A (https=)
CN (1) CN117677395A (https=)
AU (1) AU2022320922A1 (https=)
CA (1) CA3226846A1 (https=)
CL (1) CL2024000222A1 (https=)
MX (1) MX2024001276A (https=)
WO (1) WO2023006923A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
US10336802B2 (en) * 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
AR107890A1 (es) 2016-03-10 2018-06-28 Medimmune Ltd Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
AU2018314773A1 (en) * 2017-08-09 2020-03-26 Sanofi GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
WO2019060660A1 (en) * 2017-09-25 2019-03-28 Merck Sharp & Dohme Corp. CO-AGONISTS WITH EXTENDED ACTION OF GLUCAGON AND GLP-1 RECEPTORS

Also Published As

Publication number Publication date
WO2023006923A1 (en) 2023-02-02
CA3226846A1 (en) 2023-02-02
EP4376871A1 (en) 2024-06-05
AU2022320922A1 (en) 2024-01-18
JP2024529452A (ja) 2024-08-06
MX2024001276A (es) 2024-02-15
KR20240043778A (ko) 2024-04-03
CL2024000222A1 (es) 2024-08-02
US20250262279A1 (en) 2025-08-21

Similar Documents

Publication Publication Date Title
Romero-Gómez et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
Coskun et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept
Garvey et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity
US11400072B2 (en) Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN117677395A (zh) 长效glp1/胰高血糖素受体激动剂的剂量方案
US20220152055A1 (en) Methods and compositions for treating various disorders
Lee et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men
JP6561136B2 (ja) 勃起機能不全を治療又は改善するための方法及びｓｇｌｔ２阻害薬を含む医薬組成物
US12465598B2 (en) Methods of treating migraine
TW200808324A (en) Method for shortening hospital stay in patients with congestive heart failure and acute fluid overload
Jordan et al. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients
CN110958878A (zh) 用于治疗非酒精性脂肪性肝炎的licofligozin
US20210000792A1 (en) Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
US20250134864A1 (en) Methods of weight loss and preserving skeletal muscle mass
Ishay et al. Oral insulin alleviates liver fibrosis and reduces liver steatosis in patients with metabolic dysfunction-associated steatohepatitis and type 2 diabetes: Results of phase II randomized, placebo-controlled feasibility clinical trial
US20250134865A1 (en) Methods of weight loss in a subject with elevated hba1c
WO2026046202A1 (zh) Glp-1/gip肽或含有其的药物组合物的用途
CN121969358A (zh) 选择性雄激素受体调节剂（sarm）化合物在长期体重管理中的用途
Aschner Canagliflozin for the treatment of adults with Type 2 diabetes
WO2026037397A1 (zh) Glp-1类似物的医药用途
JP2026500731A (ja) 医薬組合せおよび医薬組成物、ならびにその使用方法
CN118900692A (zh) HbA1c升高的受试者的体重减轻方法
HK40081935A (en) Treatment of amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination